Literature DB >> 15098007

Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma.

Zhaosheng Lin1, Stephen D Jenson, Megan S Lim, Kojo S J Elenitoba-Johnson.   

Abstract

Completion of the human genome project has focused scientific attention on the development of methods that permit rapid characterization of proteins that are encoded by the genome. Recent improvements in two-dimensional separation techniques in combination with protein identification software/databases and mass spectrometry (MS) now permit rapid comprehensive large-scale analysis of individual proteins within complex protein mixtures. We have performed pairwise comparisons of low-grade and transformed follicular lymphomas (FLs) in order to identify proteins that may be involved in FL progression using surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometer (ProteinChip, Ciphergen Biosystems). This system utilizes preactivated differential binding surfaces to achieve multidimensional chromatography. The protein-bound chips were then analyzed by a SELDI-TOF mass spectrometer to generate protein profiles. In preliminary experiments, we established that the MS data obtained from SELDI-TOF MS were reproducible, and that reduction in sample complexity improved the ability to detect lower abundance proteins. With specific regard to FL transformation, we rapidly identified a number of potential candidate proteins involved in this process. These included an upregulated 32 kDa protein and a down-regulated 11.8 kDa protein. Protein database searches revealed several candidates, among them cyclin D3 (32.5 kDa) and caspase 3 (11.8 kDa) whose differential expression were confirmed by immunoblotting and/or immunohistochemical analysis on the primary tissue specimens. Our studies demonstrate the utility of SELDI-TOF-MS for the rapid discovery of differentially expressed proteins using femtomolar quantities of crude protein derived from biopsy material. The versatility of this methodology supports its application to the rapid discovery of potential biomarkers in a variety of cellular systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098007     DOI: 10.1038/modpathol.3800100

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Authors:  B C Tooker; R P Bowler; J M Orcutt; L A Maier; H M Christensen; L S Newman
Journal:  Occup Environ Med       Date:  2011-01-27       Impact factor: 4.402

2.  Application of MALDI imaging for the diagnosis of classical Hodgkin lymphoma.

Authors:  Kristina Schwamborn; René C Krieg; Peggy Jirak; German Ott; Ruth Knüchel; Andreas Rosenwald; Axel Wellmann
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-21       Impact factor: 4.553

Review 3.  Contributions of advanced proteomics technologies to cancer diagnosis.

Authors:  Sergio Ciordia; Vivian de Los Ríos; Juan-Pablo Albar
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

4.  Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma in China: a SELDI-TOF-MS study.

Authors:  Jianzhong Zhang; Dong Li; Yanhua Zheng; Yan Cui; Kai Feng; Jinlian Zhou; Jihua Wu
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

5.  miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.

Authors:  Mary Ann Thompson; Mick D Edmonds; Shan Liang; Sara McClintock-Treep; Xuan Wang; Shaoying Li; Christine M Eischen
Journal:  Hum Pathol       Date:  2015-11-30       Impact factor: 3.466

6.  Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses.

Authors:  S Jayanthi; S Buie; S Moore; R I Herning; W Better; N M Wilson; C Contoreggi; J L Cadet
Journal:  Mol Psychiatry       Date:  2008-05-13       Impact factor: 15.992

7.  Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning.

Authors:  Xing Zhang; Bo Wang; Xiao-shi Zhang; Zhi-ming Li; Zhong-zhen Guan; Wen-qi Jiang
Journal:  BMC Cancer       Date:  2007-12-29       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.